Robust estimation of cancer and immune cell-type proportions from bulk tumor ATAC-Seq data

Aurélie AG Gabriel,Julien Racle,Maryline Falquet,Camilla Jandus,David Gfeller
DOI: https://doi.org/10.7554/elife.94833
IF: 7.7
2024-10-10
eLife
Abstract:Assay for Transposase-Accessible Chromatin sequencing (ATAC-Seq) is a widely used technique to explore gene regulatory mechanisms. For most ATAC-Seq data from healthy and diseased tissues such as tumors, chromatin accessibility measurement represents a mixed signal from multiple cell types. In this work, we derive reliable chromatin accessibility marker peaks and reference profiles for most non-malignant cell types frequently observed in the microenvironment of human tumors. We then integrate these data into the EPIC deconvolution framework (Racle et al., 2017) to quantify cell-type heterogeneity in bulk ATAC-Seq data. Our EPIC-ATAC tool accurately predicts non-malignant and malignant cell fractions in tumor samples. When applied to a human breast cancer cohort, EPIC-ATAC accurately infers the immune contexture of the main breast cancer subtypes.
biology
What problem does this paper attempt to address?